1. Phillips KM, Barbarite E, Hoehle LP, Caradonna DS, Gray ST, Sedaghat AR. Clinical traits characterizing an exacerbation-prone phenotype in chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2019 Nov;161(5):890–6.
2. Huang JC, Chen XH, Wang ZY, Li X, Chang LH, Zhang GH. Interleukin-17A expression correlated with the prognosis of chronic rhinosinusitis with nasal polyps and the anti-interleukin-17A effect in a murine nasal polyps model. ORL J Otorhinolaryngol Relat Spec. 2020;82(5):257–67.
3. Damask CC, Ryan MW, Casale TB, Castro M, Franzese CB, Lee SE, et al. Targeted molecular therapies in allergy and rhinology. Otolaryngol Head Neck Surg. 2021 Jan;164(Suppl 1):S1–S21.
4. Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu Rev Pathol. 2017 Jan 24;12:331–57.
5. Lin H, Ba G, Tang R, Li M, Li Z, Li D, et al. Increased expression of TXNIP facilitates oxidative stress in nasal epithelial cells of patients with chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2020 Dec 29:1945892420982411. Epub ahead of print.